CLINICAL AND IMMUNOHISTOCHEMICAL FEATURES OF CROHN'S DISEASE

DOI: https://doi.org/None

N.S. Robakidze (1), O.B. Shchukina (1), A.Y. Baranovsky (1), A.O. Durnova (2), V.O. Polyakova (2) 1 -North-Western State Medical University named after I.I. Mechnikov, Kirochnaya str., 41, Saint-Petersburg, 191015, Russian Federation 2 -D.O. Ott Research Institute of Obstetrics and Gynecology, Mendeleevskaya line, 3, Saint-Petersburg, 199034, Russian Federation

Introduction. The central role in the pathogenesis of Crohn's disease (CD) is given an immune disorder. Communication immunohistochemical characteristics of the mucous membrane with the outcome of the disease has not been studied. The aim of the study. The aim was to investigate the nature of the relationship of immunohistochemical characteristics of the mucous membrane of the mouth and intestines with clinical outcomes CD. Methods. 30 patients with CD were performed by clinical, endoscopic, histologic and immunohistochemical studies. Results. A correlation was found between the presence of perianal lesions and the outcome of BC. We found the moderate expression of CD5, CD16, CD 31, CD57 in the intestinal and oral mucosa. The correlation between the expression of CD16 and the outcome of CD. Conclusion. Outcomes of Crohn's disease depends on the patient's age at the time of onset of the disease and the presence of perianal lesions. Increased expression of CD16 can be seen as a predictor of unfavorable course of the disease.
Keywords: 
Crohn's disease, outcomes, oral cavity, immunohistochemistry
Список литературы: 
  1. Chow D.K., Leong R.W., Lai L.H., Wong G.L., Leung W.K., Chan F.K., Sung J.J. Changes in Crohn’s disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm. Bowel Dis. 2008; 14: 536–41.
  2. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., Gendre J.P. Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel Dis. 2002; 8: 244–50.
  3. Van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., Ochsenkühn T., Orchard T., Rogler G., Louis E., Kupcinskas L., Mantzaris G., Travis S., Stange E. European Crohn`s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J. Crohn Colitis. 2010; 4 (1): 7–27.
  4. Nos P., Garrigues V., Bastida G., Maroto N., Ponce M., Ponce J. Outcome of patients with nonstenotic, nonfistulizing Crohn’s disease. Dig.Dis. Sci. 2004; 49: 1771–6.
  5. Hurcilava O.G., Segal` A.M., Shhukina O.B., Kondrashina E`.A., Baranovskiy A.Yu. Organizacionnye voprosy okazaniya bol`nym vospalitel`nymi zabolevaniyami kishechnika specializirovannoy gastroe`nterologicheskoy pomoshhi v Sankt-Peterburge. Vestnik Severo-Zapadnogo gosudarstvennogo medicinskogo universiteta im. I.I. Mechnikova. 2012; 1: 84–91. [Hurtsilava O. G., Segal A.M., Schukina O. B., Kondrashina E.A. Baranovsky A.Y. Organizational questions of rendering to the patient with inflammatory diseases of intestines of the specialized gastroenterologichesky help in St. Petersburg. The messenger of Northwest state medical university of I.I. Mechnikov. 2012; 1: 84–91 (in Russian)]
  6. Caprioli F., Caruso R., Sarra M., Pallone F., Monteleone G. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br. J. Pharmacol. 2012; 165 (4): 820–8.
  7. Danese S., Colombel J.F., Reinisch W., Rutgeerts P.J. Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience. Aliment. Pharmacol. Ther. 2011; 33 (8): 857–69.
  8. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006; 130 (3): 650–6.
  9. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El Yafi F.A., Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777–82.
  10. Bruyn M., Bessissow T., Billiet T., Cleynen I., R. Kirkland, X. Liu, S. Hauenstein, K. Drake, S. Singh, M. Ferrante, P. Rutgeerts, G. Van Assche, I. Arijs, G. Opdenakker, S. Vermeire. Biomarker panel for prediction of mucosal healing in patients with Crohn’s disease under infliximab therapy. Journal of Crohn’s & Colitis. 2014; 8 (1): 45–6.
  11. Solberg I.C., Vatn M.H., Hoie O., Stray N., Sauar J., Jahnsen J., Moum B., Lygren I. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin. Gastroenterol. Hepatol. 2007; 5: 1430–8.
  12. Chow D.K., Leong R.W., Lai L.H., Wong G.L., Leung W.K., Chan F.K., Sung J.J. Changes in Crohn’s disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm. Bowel Dis. 2008; 14: 536–41.
  13. Panaccione R., Colombel J.F., Louis E., Peyrin-Biroulet L., Sandborn W.J. Evolving definitions of remission in Crohn’s disease. Inflamm. Bowel Dis. 2013; 19: 1645–53.
  14. Kelvin T. Thia, William J. Sandborn, William S. Harmsen, Alan R. Zinsmeister, Edward V. Loftus Jr. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010; 139 (4): 1147–55.
  15. Zallot C., Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig. Dis. 2012; 30 (3): 67–72.
  16. Kvetnoy I.M., Robakidze N.S., Kostyuchek I.N., Shhukina O.B., Proshhaev K.I. Morfologicheskie i immunogistohimicheskie harakteristiki slizistoy obolochki polosti rta u bol`nyh s vospalitel`nymi zabolevaniyami kishechnika. Klinicheskaya medicina. 2009; 11; 49–51. [Kvetnoy I.M., Robakidze N. S., Kostyuchek I.N., Schukina O. B., Proshchayev K.I. Morphological and immunohistochemical characteristics of a mucous membrane of an oral cavity at patients with inflammatory diseases of intestines. Clinical medicine. 2009; 11; 49–51 (in Russian)]
  17. De Tena J.G., Manzano L., Leal J. Cetal. Active Crohn’s Disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null Tcells. J. of Clin. Immunology. 2004; 24 (2): 185–96.
  18. Middel P., Thelen P., Blaschke S., Polzien F., Reich K., Blaschke V., Wrede A., Hummel K.M., Gunawan B., Radzun H.J. Expression of the T-Cell chemoattractant chemokine lymphotactin in Crohn’s Disease. Am. J. Pathol. 2001; 159 (5): 1751–61.